Brazil’s pilot fast-track programme for green patents is now in its third phase. Priscila Kurdian Afonso of Di Blasi, Parente & Associados assesses whether it is meeting its goals.
As Myriad seems to have thrown in the towel in its fight to protect patents covering its BRCA diagnostic tests, LSIPR asks whether the gene patent’s days are numbered in the US, and takes a look at its fortunes in other jurisdictions.
The most recent Illicit Trade Report states that pharmaceuticals are by far the most numerous counterfeit commodity reported, and the problem is increasing. LSIPR investigates what’s being done about it.
Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports.
Brand owners may use a multitude of approaches to crack down effectively on fake drugs. Andy Leck and Ren Jun Lim discuss the challenges of anti-counterfeiting efforts in Singapore.
China, Japan and South Korea are three of the most developed markets in the world for pharmaceuticals but they still offer a wealth of opportunities for both innovators and generic drug companies. LSIPR looks at the protection available for those seeking to do business there.
Amendments to SIPO’s guidelines for the examination of utility patents may help stop the proliferation of ‘junk’ utility models in China. Wolfgang Bublak and Yingkun Brunner report.
As the largest science research institute in Japan, Riken has an important role in promoting innovation. LSIPR talked to Akihiro Fujita, director of the institute’s research cluster for innovation, about the place of intellectual property in that endeavour.
While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges.
Patent term restoration has been adopted by several jurisdictions, with varying success. Mexico faces several issues with sanitary authorisations and patent examination, so patent term restoration would be a viable remedy for patent holders. The TPP might enable this.